Understanding Mechanisms of Acquired Resistance to BIBW2992.

Trial Profile

Understanding Mechanisms of Acquired Resistance to BIBW2992.

Phase of Trial: Phase II

Latest Information Update: 13 Mar 2018

At a glance

  • Drugs Afatinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 10 Mar 2017 Status changed from active, no longer recruiting to completed.
    • 14 Nov 2016 Planned primary completion date changed from 1 Mar 2016 to 1 Jan 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top